Amuvatinib MP-470 (CAS: 850879-09-3) is a small molecule inhibitor of certain receptor tyrosine kinases. It has been developed as a potential treatment for various types of cancer, including non-small cell lung cancer, pancreatic cancer, and glioblastoma multiforme. In this article, we will discuss the chemical properties of Amuvatinib MP-470, its potential health benefits, mechanism of action, safety profile, dosing information, and more.
Chemical Properties: The chemical name of Amuvatinib MP-470 is N-(4-(2-aminopyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(trifluoromethyl)benzamide. Its molecular formula is C16H11F3N6O, and its formula weight is 368.3 g/mol. The CAS number of Amuvatinib MP-470 is 850879-09-3.
Top Ten Keywords from Google and Synonyms:
Synonyms:
Health Benefits: Amuvatinib MP-470 has shown potential health benefits as a cancer treatment. It works by inhibiting receptor tyrosine kinases, which are involved in cell signaling pathways that can promote cancer growth and survival. By blocking these proteins, Amuvatinib MP-470 may help to slow or stop the growth of cancer cells, making it a promising therapy for various types of cancer.
Potential Effects: Amuvatinib MP-470 has been studied in preclinical and clinical trials for its potential effects on cancer. Some of its key effects include:
Product Mechanism: Amuvatinib MP-470 works by inhibiting receptor tyrosine kinases, which are involved in various cellular signaling pathways. These kinases can activate other proteins inside the cell, leading to changes in cell growth, proliferation, and survival. By blocking receptor tyrosine kinases, Amuvatinib MP-470 can disrupt these pathways and potentially slow or stop the growth of cancer cells.
Safety: Like all drugs, Amuvatinib MP-470 has some potential safety concerns. It is important to note that the safety of this product is still a subject of active research and should not be considered as a fully approved product yet. However, some of the known safety issues include:
Side Effects: Some of the possible side effects of Amuvatinib MP-470 include nausea, vomiting, diarrhea, fatigue, headache, and decreased appetite. More serious adverse events reported in clinical trials include neutropenia, anemia, thrombocytopenia, and renal dysfunction. Again, these side effects call for more data to be generated before it can be concluded that Amuvatinib MP-470 would be safe to use as a full-fledged medication.
Dosing Information: The optimal dosages of Amuvatinib MP-470 are still being studied but initial reports suggest that 300 mg twice daily dose via oral route might be a standard dose.
Conclusion: In conclusion, Amuvatinib MP-470 is a small molecule inhibitor with promising potential as a cancer treatment. It works by inhibiting receptor tyrosine kinases, which are involved in various cellular signaling pathways that regulate cell growth and survival. Although still in the early stages of clinical development, Amuvatinib MP-470 has shown efficacy in reducing
